11 Oversold NASDAQ Stocks to Buy Right Now

Page 10 of 10

1. Vaxcyte, Inc. (NASDAQ:PCVX)

Perf YTD: -59.81%

Analyst Upside: 311.10%

Number of Hedge Fund Holders: 50

Vaxcyte, Inc. (NASDAQ:PCVX) is a clinical-stage vaccine innovation company that develops high-fidelity vaccines. It develops broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. The company re-engineers the creation of highly complex vaccines through advanced chemistry and modern synthetic techniques.

Needham analyst Joseph Stringer maintained a bullish stance on Vaxcyte, Inc. (NASDAQ:PCVX), giving it a Buy rating on April 1. The analyst said that the company’s recent VAX-24 Phase 2 infant study data has bolstered confidence in its success with encouraging results. The overall expectations around the VAX-31 Phase 2 infant program are also positive, pointing to further advancements in their vaccine development pipeline.

The analyst further reasoned that Vaxcyte, Inc. (NASDAQ:PCVX) is committed to expanding its product offerings, and the introduction of the VAX-XL program, which could potentially enhance its market position, corroborates that. These factors combined support a favorable outlook for the company’s performance.

Overall, PCVX ranks first among the oversold NASDAQ stocks to buy right now. While we acknowledge the potential of oversold NASDAQ stocks, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than PCVX but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

Page 10 of 10